Clinical Trials

 

Disease
Plaque Psoriasis
Title
An Open-label, Multi-center, 52-Week, Long-term Study to Evaluate the Safety and Efficacy of 50 mcg/g M518101 in Subjects with Plaque Psoriasis
Inclusion*
A clinical diagnosis of stable plaque psoriasis of at least 6 months and up to 20% of body surface area covered in plaques.
Study Contact
Principal Investigator
 Andrea L. Neimann, MD, MSCE
Objective
This study will look at how M518101 (the study drug) works on psoriasis skin plaques, as well as evaluating the safety, efficacy (how well M518101 works), and tolerability of M518101 as treatment of plaque psoriasis.
Status
RECRUITING
Age Requirement
18 years+
Gender
males and females
 
Disease
Atopic Dermatitis
Title
A phase II, randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of CIM331 in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
Inclusion*
A diagnosis of moderate to severe atopic dermatitis who are inadequately controlled by or intolerant to topical therapy
Study Contact
Principal Investigator
Andrea L. Neimann, MD, MSCE
Objective
This study is being carried out to see if the new experimental drug called CIM331 is safe and effective in subjects with moderate to severe atopic dermatitis.
Status RECRUITING
Age Requirement 18-65 years of age
Gender males and females 
 

 *: Required for all studies: females of childbearing age must have a negative pregnancy test at screening and agree to use at least two forms of contraception during their participation in the study.

For complete information regarding inclusion and exclusion criteria, please call (212) 263-5244; (212) 263-6881; or email dermpharm@nyumc.org